Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

10d ago, source: MarketBeat on MSN

Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biotechnology company specializing in treating liver disease and obesity.

Altimmune, Inc. (ALT)

2d ago, source: Yahoo Finance

March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial ...

Buy Altimmune's Potential Market Disruption With Pemvidutide

7d ago, source:

Altimmune's Pemvidutide is looking for partners, as it has shown promising results in clinical trials for obesity and ...

The Impact of Market Fluctuations on Altimmune Inc’s (ALT) Stock

3d ago, source: newsheater

Based on Altimmune Inc (ALT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -112.98. The debt to equity ratio resting ...

Altimmune, Inc. (ALT) Q4 2023 Earnings Call Transcript

23d ago, source: Seeking Alpha

Good day, ladies and gentlemen, and welcome to the Altimmune Inc. Full Year and Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being ...

Real-Time Update: Altimmune Inc (ALT) Stock Navigates the Market with Up-to-Date Data

10d ago, source: newsheater

Many brokerage firms have already submitted their reports for ALT stocks, with Goldman repeating the rating for ALT by listing it as a “Neutral.” The predicted price for ALT in the upcoming period, ...

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

23d ago, source: Business Insider

March 27, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December ...

Altimmune, Inc. Common Stock (ALT)

2mon ago, source: Nasdaq

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...

altimmune inc.

24d ago, source: Fox Business

Fox News medical contributor Dr. Janette Nesheiwat broke down to "Kudlow" that a wider range of coronavirus vaccine options would be beneficial for pandemic recovery as well as personal health.